How this woman is leading the next biotech revolution

LONDON: Pioneering a new way to make medicines — by creating chemical building blocks entirely new to nature — may sound like a lot for a young company to take on. But Constructive Bio’s ambitions don’t stop there.

It has also set itself the task of replacing today’s wasteful industrial processes with sustainable microbial factories. These so-called biofactories could be used to make materials for everything from pesticides to biodegradable plastics.

Turning the biotech company’s cutting-edge science into commercial reality is the job of the scientist turned chief executive Ola Wlodek.

She characterises the work of Constructive Bio, one of a handful of synthetic biology companies, as at the forefront of a “biorevolution” akin to a fourth industrial revolution.

“We’re working towards a future where ingredients, for example for medicines, are not made by a dirty factory, but instead from tiny and natural machines — cells,” Wlodek, 39, said.

Wlodek initially came to the UK from Poland in 2009 to study for her PhD. After working as a scientist for several Cambridge biotechs, “I quickly found out that I’m not suited for a purely academic career, and I wanted to work in business,” she said.

Joining Constructive Bio, she took on the task of commercialising science conceived by the venture’s founder, Professor Jason Chin. His breakthroughs enable it to write an organism’s DNA, its instruction manual, from scratch. This allows it to programme cells to create entirely new molecules, in a process it says is more efficient and produces less chemical waste than other techniques.

In 2021 Chin spun the business out of the Medical Research Council’s Laboratory of Molecular Biology — a Cambridge University biotech hotbed whose scientists have been awarded 12 Nobel prizes to date. These scientists include Sir Greg Winter, who joined Constructive Bio’s board last year.

Wlodek has set about attracting pharmaceutical company partners to start putting its science to work. One of these partnerships is focused on the development of more efficient and cost-effective methods for manufacturing molecules such as semaglutide, the active ingredient in Ozempic, the diabetes-treatment-turned-weight-loss “wonder” drug.

Wlodek’s team is also working with another pharma business to improve cutting-edge drugs called antibody-drug conjugates, or ADCs, to more directly target and kill cancer cells, all while leaving healthy cells intact.

The company is among eight biotech companies that don’t yet have the revenue growth to rank on this year’s Sunday Times 100 Tech — but deserve special recognition nonetheless. The success of biotech start-ups like Constructive Bio tends to be measured by scientific breakthroughs and funds raised rather than revenues, which typically come more slowly than in other industries.

“The problem with biology is that it requires time and patience from investors,” Wlodek said. In Constructive Bio’s case, Chin spent 20 years developing his ideas in the lab before seeking to spin out the business.

That patience can pay off, and in Wlodek’s words, the financial rewards can be “huge”. For instance, another pioneer sharing the synthetic biology niche with Constructive Bio is Ambrx, which was built in part on work done by Chin. Ambrx was snapped up for $2 billion by Johnson & Johnson last March.

Investors will be hoping that Constructive Bio proves similarly lucrative. A syndicate led by Ahren, OMX Ventures and Paladin Capital Group handed the venture $58 million in funding in September, in one of the largest UK biotech institutional rounds in recent years.

Like many biotech start-up bosses, Wlodek has an eye to the US and highlights that the company’s investors hail from both sides of the Atlantic. She said: “2024 was not the easiest year to raise venture capital and US investors still tend to have deeper pockets than UK or European investors. Also, frankly speaking, there have been to date more biotech successes in the US.”

The fundraising, which takes Constructive Bio’s total backing to $75 million, also brought Winter, a biotech Nobel laureate, onboard. He has has founded three biotech companies, including Nasdaq-listed Bicycle Therapeutics, valued at about $1 billion. “He’s not only a scientific brain, but also a savvy commercial entrepreneur,” Wlodek said.

A stock market listing is a well-trodden path for capital-hungry biotechs and could be in Constructive Bio’s future. “If we want to build a big, sustainable commercial company, at some point it will require access to the public markets or equivalent funds,” Wlodek said.

Alongside its plans to both licence its technology to partners and develop its own pipeline of products, the company is considering creating its own “biofactory” in Cambridge, which Wlodek said would cost “tens of millions”.

For now, though, Wlodek said, “We’re focusing on getting our hands dirty and delivering on the technological breakthroughs.”